These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 31042295

  • 1. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ.
    J Psychosoc Nurs Ment Health Serv; 2019 May 01; 57(5):11-14. PubMed ID: 31042295
    [Abstract] [Full Text] [Related]

  • 2. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec 01; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

  • 3. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H, Henchcliffe C.
    Expert Rev Clin Pharmacol; 2018 Mar 01; 11(3):209-217. PubMed ID: 29338466
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N, Jankovic J.
    Drugs; 2018 Apr 01; 78(5):525-541. PubMed ID: 29484607
    [Abstract] [Full Text] [Related]

  • 5. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L.
    Expert Rev Neurother; 2018 Apr 01; 18(4):323-332. PubMed ID: 29557243
    [Abstract] [Full Text] [Related]

  • 6. Tardive Dyskinesia: Treatment Update.
    Arya D, Khan T, Margolius AJ, Fernandez HH.
    Curr Neurol Neurosci Rep; 2019 Aug 16; 19(9):69. PubMed ID: 31420757
    [Abstract] [Full Text] [Related]

  • 7. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC, Hauser RA.
    Expert Opin Pharmacother; 2017 Aug 16; 18(12):1279-1287. PubMed ID: 28699794
    [Abstract] [Full Text] [Related]

  • 8. Valbenazine in the treatment of tardive dyskinesia.
    Witek N, Comella C.
    Neurodegener Dis Manag; 2019 Apr 16; 9(2):73-81. PubMed ID: 30724115
    [Abstract] [Full Text] [Related]

  • 9. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP, Baker DE, Levien TL.
    Consult Pharm; 2018 Apr 01; 33(4):201-209. PubMed ID: 29609698
    [Abstract] [Full Text] [Related]

  • 10. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug 01; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 11. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Aug 01; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 12. Two New Drugs for Tardive Dyskinesia Hit the Market.
    Morrow T.
    Manag Care; 2018 Jan 01; 27(1):35-36. PubMed ID: 29369770
    [Abstract] [Full Text] [Related]

  • 13. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP.
    J Clin Psychiatry; 2019 Dec 17; 81(1):. PubMed ID: 31851437
    [Abstract] [Full Text] [Related]

  • 14. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug 17; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 15. Valbenazine for the treatment of tardive dyskinesia.
    Müller T.
    Expert Rev Neurother; 2017 Dec 17; 17(12):1135-1144. PubMed ID: 28971695
    [Abstract] [Full Text] [Related]

  • 16. Valbenazine for Tardive Dyskinesia.
    Freudenreich O, Remington G.
    Clin Schizophr Relat Psychoses; 2017 Dec 17; 11(2):113-119. PubMed ID: 28742396
    [Abstract] [Full Text] [Related]

  • 17. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 18. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T.
    Expert Opin Investig Drugs; 2015 Jun 01; 24(6):737-42. PubMed ID: 25809133
    [Abstract] [Full Text] [Related]

  • 19. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May 22; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract] [Full Text] [Related]

  • 20. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.
    N Engl J Med; 2017 Jun 29; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.